Brivaracetam
Back to searchMolecule Structure
Scientific Name
Brivaracetam
Description of the Drug
Brivaracetam is an anticonvulsant used for the treatment of partial-onset seizures that functions by binding to synaptic vesicle glycoprotein 2A (SV2A) in the brain.
Source: DrugBank Online – DrugBank.com. Retrieved 2023-03-10 from
http://www.drugbank.ca/drugs/DB05541
http://www.drugbank.ca/drugs/DB05541
Brand Name(s)
Briviact
Company Owner(s)
Sunshine Lake Pharma Co Ltd, Ucb Inc
Mechanism(s) Of Action
Target Name | Target Type | Action Type | Target ChEMBL ID |
---|---|---|---|
Synaptic vesicle glycoprotein 2A | SINGLE PROTEIN | MODULATOR | CHEMBL1998 |
Clinical Trial(s)
Unichem Links
SureChEMBL | SCHEMBL122081 | |
PharmGKB | PA166153491 | |
DrugBank | DB05541 | |
PubChem: Thomson Pharma | 14797750 | |
PubChem | 9837243 | |
Nikkaji | J2.411.659J | |
BindingDB | 50422531 | |
DrugCentral | 5068 | |
Guide to Pharmacology | 9041 | |
rxnorm | BRIVIACT | BRIVARACETAM |
PubChem: Drugs of the Future | 22395457 | |
ChEBI | 133013 | |
ZINC | ZINC000003979899 |